|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SUCO |
Gene summary for SUCO |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SUCO | Gene ID | 51430 |
| Gene name | SUN domain containing ossification factor | |
| Gene Alias | C1orf9 | |
| Cytomap | 1q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0001503 | UniProtAcc | B4DYM4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51430 | SUCO | CCI_1 | Human | Cervix | CC | 7.31e-03 | 6.60e-01 | 0.528 |
| 51430 | SUCO | CCI_3 | Human | Cervix | CC | 3.51e-02 | 5.68e-01 | 0.516 |
| 51430 | SUCO | LZE4T | Human | Esophagus | ESCC | 5.24e-10 | 4.11e-01 | 0.0811 |
| 51430 | SUCO | LZE7T | Human | Esophagus | ESCC | 8.32e-11 | 7.76e-01 | 0.0667 |
| 51430 | SUCO | LZE8T | Human | Esophagus | ESCC | 6.01e-05 | 1.29e-01 | 0.067 |
| 51430 | SUCO | LZE20T | Human | Esophagus | ESCC | 2.79e-04 | 1.15e-01 | 0.0662 |
| 51430 | SUCO | LZE22T | Human | Esophagus | ESCC | 4.05e-06 | 3.37e-01 | 0.068 |
| 51430 | SUCO | LZE24T | Human | Esophagus | ESCC | 2.72e-18 | 4.08e-01 | 0.0596 |
| 51430 | SUCO | LZE21T | Human | Esophagus | ESCC | 8.09e-04 | 4.25e-01 | 0.0655 |
| 51430 | SUCO | P1T-E | Human | Esophagus | ESCC | 2.83e-10 | 6.07e-01 | 0.0875 |
| 51430 | SUCO | P2T-E | Human | Esophagus | ESCC | 2.02e-48 | 9.99e-01 | 0.1177 |
| 51430 | SUCO | P4T-E | Human | Esophagus | ESCC | 2.80e-27 | 7.04e-01 | 0.1323 |
| 51430 | SUCO | P5T-E | Human | Esophagus | ESCC | 1.68e-16 | 4.54e-01 | 0.1327 |
| 51430 | SUCO | P8T-E | Human | Esophagus | ESCC | 1.92e-22 | 3.17e-01 | 0.0889 |
| 51430 | SUCO | P9T-E | Human | Esophagus | ESCC | 1.18e-15 | 3.59e-01 | 0.1131 |
| 51430 | SUCO | P10T-E | Human | Esophagus | ESCC | 3.35e-20 | 4.18e-01 | 0.116 |
| 51430 | SUCO | P11T-E | Human | Esophagus | ESCC | 1.05e-12 | 7.71e-01 | 0.1426 |
| 51430 | SUCO | P12T-E | Human | Esophagus | ESCC | 5.46e-17 | 3.21e-01 | 0.1122 |
| 51430 | SUCO | P15T-E | Human | Esophagus | ESCC | 1.42e-34 | 7.01e-01 | 0.1149 |
| 51430 | SUCO | P16T-E | Human | Esophagus | ESCC | 2.70e-45 | 7.79e-01 | 0.1153 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00016497 | Cervix | CC | osteoblast differentiation | 47/2311 | 229/18723 | 2.88e-04 | 3.11e-03 | 47 |
| GO:0045667 | Cervix | CC | regulation of osteoblast differentiation | 29/2311 | 132/18723 | 1.32e-03 | 1.05e-02 | 29 |
| GO:00015037 | Cervix | CC | ossification | 71/2311 | 408/18723 | 1.67e-03 | 1.28e-02 | 71 |
| GO:00487712 | Cervix | CC | tissue remodeling | 34/2311 | 175/18723 | 4.68e-03 | 2.82e-02 | 34 |
| GO:0045669 | Cervix | CC | positive regulation of osteoblast differentiation | 16/2311 | 69/18723 | 8.75e-03 | 4.48e-02 | 16 |
| GO:000164918 | Esophagus | ESCC | osteoblast differentiation | 140/8552 | 229/18723 | 1.63e-06 | 1.95e-05 | 140 |
| GO:000150317 | Esophagus | ESCC | ossification | 232/8552 | 408/18723 | 3.00e-06 | 3.40e-05 | 232 |
| GO:00456675 | Esophagus | ESCC | regulation of osteoblast differentiation | 77/8552 | 132/18723 | 2.28e-03 | 1.00e-02 | 77 |
| GO:00329631 | Esophagus | ESCC | collagen metabolic process | 62/8552 | 104/18723 | 2.90e-03 | 1.22e-02 | 62 |
| GO:00456695 | Esophagus | ESCC | positive regulation of osteoblast differentiation | 43/8552 | 69/18723 | 3.93e-03 | 1.59e-02 | 43 |
| GO:000164911 | Liver | HCC | osteoblast differentiation | 115/7958 | 229/18723 | 1.08e-02 | 3.99e-02 | 115 |
| GO:000150310 | Oral cavity | OSCC | ossification | 203/7305 | 408/18723 | 5.54e-06 | 6.19e-05 | 203 |
| GO:000164910 | Oral cavity | OSCC | osteoblast differentiation | 118/7305 | 229/18723 | 7.51e-05 | 5.85e-04 | 118 |
| GO:0032963 | Oral cavity | OSCC | collagen metabolic process | 54/7305 | 104/18723 | 5.00e-03 | 1.96e-02 | 54 |
| GO:00487713 | Oral cavity | OSCC | tissue remodeling | 84/7305 | 175/18723 | 9.39e-03 | 3.36e-02 | 84 |
| GO:00456674 | Oral cavity | OSCC | regulation of osteoblast differentiation | 65/7305 | 132/18723 | 1.06e-02 | 3.60e-02 | 65 |
| GO:000150322 | Oral cavity | EOLP | ossification | 70/2218 | 408/18723 | 8.89e-04 | 6.81e-03 | 70 |
| GO:000164922 | Oral cavity | EOLP | osteoblast differentiation | 41/2218 | 229/18723 | 4.47e-03 | 2.42e-02 | 41 |
| GO:0032964 | Oral cavity | EOLP | collagen biosynthetic process | 13/2218 | 51/18723 | 5.43e-03 | 2.82e-02 | 13 |
| GO:0010712 | Oral cavity | EOLP | regulation of collagen metabolic process | 12/2218 | 47/18723 | 7.31e-03 | 3.54e-02 | 12 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SUCO | SNV | Missense_Mutation | novel | c.2890N>G | p.Ser964Ala | p.S964A | Q9UBS9 | protein_coding | tolerated_low_confidence(0.21) | benign(0.011) | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR |
| SUCO | SNV | Missense_Mutation | c.28C>G | p.Leu10Val | p.L10V | Q9UBS9 | protein_coding | tolerated_low_confidence(0.22) | benign(0) | TCGA-A8-A0A6-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | epirubicin | CR | |
| SUCO | SNV | Missense_Mutation | novel | c.3992G>A | p.Gly1331Asp | p.G1331D | Q9UBS9 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.995) | TCGA-A8-A0A9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
| SUCO | SNV | Missense_Mutation | c.715G>C | p.Asp239His | p.D239H | Q9UBS9 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.874) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SUCO | SNV | Missense_Mutation | c.3121G>A | p.Glu1041Lys | p.E1041K | Q9UBS9 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SUCO | SNV | Missense_Mutation | rs770645022 | c.1105A>G | p.Lys369Glu | p.K369E | Q9UBS9 | protein_coding | deleterious_low_confidence(0.04) | possibly_damaging(0.542) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SUCO | SNV | Missense_Mutation | c.3497N>C | p.Val1166Ala | p.V1166A | Q9UBS9 | protein_coding | deleterious(0.03) | benign(0.036) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SUCO | SNV | Missense_Mutation | c.2617N>C | p.Glu873Gln | p.E873Q | Q9UBS9 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.975) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
| SUCO | SNV | Missense_Mutation | c.2281G>C | p.Glu761Gln | p.E761Q | Q9UBS9 | protein_coding | tolerated(0.09) | benign(0.067) | TCGA-BH-A209-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SUCO | SNV | Missense_Mutation | c.3101N>T | p.Thr1034Ile | p.T1034I | Q9UBS9 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-D8-A140-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin+cyclophosphamid | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |